CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENTPRNewsWire • 12/08/25
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATEPRNewsWire • 10/28/25
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIOPRNewsWire • 10/20/25
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership DealPRNewsWire • 10/20/25
CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.PRNewsWire • 10/13/25
TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIAPRNewsWire • 09/29/25
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAKPRNewsWire • 08/04/25
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATEPRNewsWire • 07/29/25
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual ConferencePRNewsWire • 06/23/25
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTSPRNewsWire • 05/27/25
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCHPRNewsWire • 05/13/25
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATEPRNewsWire • 04/29/25
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific ConferencePRNewsWire • 03/19/25